Pharma Mar, S.A. (BME:PHM)
Spain
· Delayed Price · Currency is EUR | Market Cap | 1.30B |
| Revenue (ttm) | 179.28M |
| Net Income (ttm) | 34.01M |
| Shares Out | 17.21M |
| EPS (ttm) | 1.95 |
| PE Ratio | 38.70 |
| Forward PE | 21.10 |
| Dividend | 0.80 (1.06%) |
| Ex-Dividend Date | Jun 25, 2025 |
| Volume | 38,010 |
| Average Volume | 34,702 |
| Open | 75.05 |
| Previous Close | 75.15 |
| Day's Range | 74.90 - 77.45 |
| 52-Week Range | 65.00 - 105.80 |
| Beta | 0.25 |
| RSI | 48.68 |
| Earnings Date | Feb 27, 2026 |
About Pharma Mar
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin ... [Read more]
Financial Performance
In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.
Financial StatementsNews
Pharma Mar SA (PHMMF) Q4 2024 Earnings Call Highlights: Record Profits and Strategic Advances
Pharma Mar SA (PHMMF) Q4 2024 Earnings Call Highlights: Record Profits and Strategic Advances
Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript
Pharma Mar, S.A. (OTCPK:PHMMF) Q4 2022 Earnings Conference Call March 1, 2023 7:00 AM ET Company Participants Jose Luis - Head, Investor Relations & Capital Markets Maria Luisa de Francia - Chief Fina...
Pharma Mar, S.A. (PHMMF) Management on Q4 2021 Results - Earnings Call Transcript
Pharma Mar, S.A. (PHMMF) Management on Q4 2021 Results - Earnings Call Transcript